Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Construction of a novel cuproptosis-related gene signature for predicting prognosis and estimating tumor immune microenvironment status in papillary thyroid carcinoma

Fig. 3

Differences in tumor immune microenvironments between C1 and C2. a The differences in stromal and immune scores and tumor purity between C1 and C2 based on the ESTIMATE algorithm. b The differences in MHC molecules, effector cells, immunosuppressive cells, and immune checkpoints between C1 and C2 based on the IPS algorithm. c The differences in the 22 types of immune cell infiltrating abundances between C1 and C2 based on the CIBERSORT algorithm. d The differences of immune cell infiltrating abundances between C1 and C2 based on the quanTIseq algorithm. e The differences in ICB therapy scores between C1 and C2 based on the ImmuCellAI algorithm. f The differences in the expression levels of the 33 known types of immune checkpoint molecules between C1 and C2. C1, cluster1; C2, cluster2; MHC, major histocompatibility complex; ICB, immune checkpoint blockade. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001

Back to article page